Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

Patient-reported outcomes from the EMBER-3 study demonstrated that patients with ESR1 mutations experienced better global health status/quality of life and physical functioning with imlunestrant compared to standard of care, which was consistent with the study’s efficacy results.